by
Thomas Dworetzky, Contributing Reporter | May 24, 2017
In April,
a study on COPD treatment co-sponsored by Philips, found that the combination of noninvasive ventilation and home oxygen therapy can prolong time to readmission or death for patients who have had a life-threatening respiratory event.
"Noninvasive ventilation (NIV) assists patients with their breathing by providing a prescribed pressure or volume of air during inhalation," Dr. Teofilo Lee-Chiong, chief medical liaison for Philips, and professor of medicine at National Jewish Hospital and the University of Colorado, told HCB News. "Newer technologies, such as the AVAPS-AE mode used in the study with Philips Trilogy, are more responsive to the patient's ever-changing breathing needs."
Ad Statistics
Times Displayed: 19373
Times Visited: 365 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The study found a $402,981 savings over 30 days and a $449,101 savings over 90 days for 250 patients. Further, in a related payor-based case analysis of 100,000 patients, the study calculated a three-year savings of $326 million for patients treated with the advanced care NIV, and $1.04 billion in savings compared to no NIV treatment.
Back to HCB News
